Emerging role of pemetrexed in ovarian cancer

Federica Tomao, Pierluigi Benedetti Panici, Luigi Frati, Silverio Tomao

Research output: Contribution to journalArticlepeer-review


The current treatment of choice of epithelial ovarian cancer involves aggressive tumor cytoreductive surgery followed by platinum- and taxane-based chemotherapy; however, despite the encouraging activity of these agents, most ovarian carcinomas relapse and many patients die from drug-resistant disease. After the failure of platinum- and taxane-based schedules, several cytotoxic agents have demonstrated activity in advanced ovarian cancer but none were able to induce significant and durable responses. Among the new cytotoxic agents, pemetrexed plays an emerging role in different tumors, demonstrating competitive activity and a promising safety profile. In ovarian cancer, pemetrexed has been investigated, with encouraging results, as a single agent and in association with platinum compounds; moreover, the drug has shown interesting activity both in platinum-sensitive and platinum-resistant ovarian cancer. According to these clinical results it appears reasonable to explore the combination of pemetrexed with other cytotoxic agents and also with targeted therapies in relapsed ovarian cancer patients.

Original languageEnglish
Pages (from-to)1727-1735
Number of pages9
JournalExpert Review of Anticancer Therapy
Issue number12
Publication statusPublished - Dec 2009


  • Carboplatin
  • Chemotherapy
  • Cisplatin
  • Epithelial ovarian cancer
  • Overall survival
  • Pemetrexed
  • Recurrent disease
  • Response rate
  • Targeted therapies
  • Taxanes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology


Dive into the research topics of 'Emerging role of pemetrexed in ovarian cancer'. Together they form a unique fingerprint.

Cite this